

Gp #1634

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name		Steven F. Goldstein	
Signature		[Signature]	
		Date	January 14, 2003
INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(e) Address to: Assistant Commissioner for Patents Washington, D.C. 20231		Attorney Docket	2300-1663
		First Named Inventor	KENNEDY, GIULIA
		Application Number	09/883,152
		Confirmation No.	8227
		Filing Date	June 15, 2001
		Group Art Unit	1634
		Examiner Name	SAKELARIS, SALLY
		Title:	"POLYNUCLEOTIDES RELATED TO COLON CANCER"

RECEIVED
JAN 23 2003
TECH CENTER 1800/2900

Sir:

Applicants submit herewith patents and/or publications which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. While this Statement may be "material" pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such. A listing of patents and/or publications is shown on enclosed Form PTO-SB/08A and a copy of each patent and/or publication is also enclosed.

Each item of information contained in the Information Disclosure Statement filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 C.F.R. 1.97(e)(1)). A copy of the communication is enclosed for the Examiner's convenience.

The Examiner is requested to make the citations listed on the enclosed PTO-SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO-SB/08A, indicating the references have been considered and made of record herein.

No fee is believed due as this statement is being submitted within three months of the mailing date of the enclosed foreign communication. However, if it is determined that fees are required, the Commissioner is hereby authorized to charge any necessary fees associated with this communication or credit any overpayment to Deposit Account No. 50-0815, Order No. 2300-1663.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: January 14, 2003

By: [Signature]
James S. Keddie, Ph.D., Reg. No. 48,920

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231
F:\DOCUMENT\2300\1663\IDS Statement Foreign.doc

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to this collection of information unless it displays a currently valid control number.</p> <p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	09/883,152
				Filing Date	June 15, 2001
				First Named Inventor	KENNEDY, GIULIA
				Group Art Unit	1634
				Examiner Name	SAKELARIS, SALLY
Attorney Docket Number	2300-1663				
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		5,981,279		Weiss	11-09-1999	
		6,007,991		Sivaraman et al.	12-28-1999	

[illegible]


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known		
		Application Number	09/883,152	
		Filing Date	June 15, 2001	
		First Named Inventor	KENNEDY, GIULIA	
		Group Art Unit	1634	
		Examiner Name	SAKELARIS, SALLY	
Sheet	2	of	Attorney Docket Number	2300-1663

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		Bougueleret, et al., "Secreted Protein EST Coding Sequence 108-002-5-0-F4-FL" Database Accession number AAZ40784; XP002214384 Database EBI Online EMBL (January 18, 2000).
		Radinsky et al., "Level and Function of Epidermal Growth Factor Receptor Predict the Metastatic Potential of Human Colon Carcinoma Cells" Clinical Cancer Research Vol. 1, No. 1 Pages 19-31, XP002099964 (January 1995).
		Rosenthal, et al., "Human Prostate Tumor cDNA Library Derived EST Fragment #27" Database Accession number AAZ52884; XP002214383 Database EBI Online EMBL (March 14, 2000).
		Yeatman, et al., "Identification of a Differentially-Expressed Message Associated with Colon Cancer Liver Metastasis Using an Improved Method of Differential Display" Nucleic Acid Res., Vol. 23, No. 19, pgs. 4007-4008, XP002214382 (1995)

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.